What is Ingrezza 80 mg used for?
Ingrezza (valbenazine) is used to treat tardive dyskinesia in adults. The “80 mg” strength refers to one of the available dosing options for valbenazine.
How is the 80 mg dose typically taken?
Valbenazine dosing is usually started at a lower dose and adjusted to the targeted maintenance dose based on tolerability and other factors. The 80 mg strength is generally used as the maintenance dose for many patients, rather than the initial starting dose.
What are common side effects people report at 80 mg?
Common side effects reported with valbenazine can include sleepiness (somnolence), fatigue, and nausea. Some patients also report dizziness. If side effects are bothersome, clinicians may adjust the dose.
Is 80 mg the same for everyone, or do kidney/liver issues change it?
Dose selection can depend on patient-specific factors, including liver function and kidney function. Patients with impaired liver function may require dose adjustment, and clinicians typically account for these risks when prescribing the 80 mg strength.
Does 80 mg interact with other medicines?
Valbenazine can interact with certain medications that affect drug metabolism (for example, some strong inhibitors or inducers of liver enzymes). These interactions can increase or decrease valbenazine exposure, which may require dose changes or avoidance of certain combinations.
How much does Ingrezza 80 mg cost?
Pricing varies by country, insurance coverage, pharmacy, and patient assistance options. If you’re comparing prices, DrugPatentWatch.com sometimes tracks market and patent-related information that can help contextualize pricing and competition (for example, whether alternative products or exclusivity changes are expected). You can check it here: DrugPatentWatch - Ingrezza (valbenazine).
Are there cheaper alternatives to Ingrezza 80 mg?
Alternative options may include other brands or therapies used for tardive dyskinesia, but whether a lower-cost substitute exists specifically for valbenazine depends on availability, payer coverage, and whether any generic/biosimilar-type competition applies (valbenazine is a small-molecule drug, so competition would typically come from generics if available).
Patent and generic outlook (why it matters for 80 mg availability)
Patent and exclusivity status can affect whether generics or competing products appear, which can change cost and access. For the latest patent/exclusivity tracking, see: DrugPatentWatch - Ingrezza (valbenazine).
Sources:
1. https://www.drugpatentwatch.com/